LACTNET Archives

Lactation Information and Discussion

LACTNET@COMMUNITY.LSOFT.COM

Options: Use Forum View

Use Monospaced Font
Show Text Part by Default
Show All Mail Headers

Message: [<< First] [< Prev] [Next >] [Last >>]
Topic: [<< First] [< Prev] [Next >] [Last >>]
Author: [<< First] [< Prev] [Next >] [Last >>]

Print Reply
Subject:
From:
"Valerie W, McClain" <[log in to unmask]>
Reply To:
Lactation Information and Discussion <[log in to unmask]>
Date:
Mon, 1 Dec 2003 05:44:58 EST
Content-Type:
text/plain
Parts/Attachments:
text/plain (61 lines)
Just wanted to share this patent called, "Reduction of gastrointestinal
disease-producing orgnaisms with sialic acid and gangliosides," with the inventor
being Ann C. Ettinger and filed in 1985.  This is a patent for a "mother's milk
substitute."  The Riordan/Auerbach text, "Breastfeeding and Human Lactation,"
states that "congenital or primary lactase deficiency is exceedingly rare;
some authorities question its existence." (page 129--second edition)  The infant
formula industry owns human milk component patents (mostly methods to produce
them synthetically), they have funded alot of human milk research.  They know
the science.  They should be the ones to produce the evidence that states
their "public position."

This particular patent has no assignee.  And the inventor is unknown to me.
So I do not know whether this ever became a product.  But its interesting to
learn what has been know for years about human milk.  I think this information
is like a state secret--heaven forbid the public get ahold of this
information.
Valerie W. McClain, IBCLC


http://www.uspto/patft/index.html
patent # 4762822

"A recent report by Koopman et al., Am. J. Public Health, May 1985, compared
data on 143 babies with gastrointestinal illness and 143 babies free of such
illness. Their case-control study indicated that babies fed on formula were at
6 times the risk of babies on breast milk and 2.5 times the risk of babies on
cows'milk.

Among those substances in human milk reported to provide anti-infective
properties are a growth enhancer for lactobacillus, an antistaphlococcal agent,
immunoglobulins, complement components, lysozyme, lactoperoxidose, lactoferrin,
macrophages, lymphocytes and lipids (Kabara, above). However, whether these
factors protect the mammary gland from infection or confer infection resistance
on the child is unknown (Kabara, above).

The gut of the breast-fed human infant is enriched with lactobacilli in
comparison to the gut of infants who are not breast-fed. This difference has been
attributed to a lactobacillus growth factor and the high concentration of
lactose in human milk, along with its low bulk, low protein content and low
buffering capacity. It has been postulated that the high lactose concentration allows
sufficient lactose to pass to the intestine to support the growth of lactose
fermenters that produce acid conditions and encourage lactobacilli. The large
population of lactobacilli alters growth conditions in the gut creating an
environment in which diarrhea-producing organisms are less likely to grow (Welsh,
above)."




             ***********************************************

To temporarily stop your subscription: set lactnet nomail
To start it again: set lactnet mail (or digest)
To unsubscribe: unsubscribe lactnet
All commands go to [log in to unmask]

The LACTNET mailing list is powered by L-Soft's renowned
LISTSERV(R) list management software together with L-Soft's LSMTP(TM)
mailer for lightning fast mail delivery. For more information, go to:
http://www.lsoft.com/LISTSERV-powered.html

ATOM RSS1 RSS2